Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2

The Pfizer/BioNtech Comirnaty vaccine (BNT162b2 mRNA COVID-19) against SARS-CoV-2 is currently in use in Italy. Antibodies to evaluate SARS-CoV-2 infection prior to administration are not routinely tested; therefore, two doses may be administered to asymptomatic previously exposed subjects. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvaggio, Marcello, Fusina, Federica, Albani, Filippo, Salvaggio, Maurizio, Beschi, Rasula, Ferrari, Emanuela, Costa, Alberto, Agnoletti, Laura, Facchi, Emanuela, Natalini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472660/
https://www.ncbi.nlm.nih.gov/pubmed/34575315
http://dx.doi.org/10.3390/jcm10184204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472660/
https://www.ncbi.nlm.nih.gov/pubmed/34575315
http://dx.doi.org/10.3390/jcm10184204

Ejemplares similares